- AU$11.95m
- AU$2.93m
- AU$7.71m
Australia's Immuron hits near 1.5-month high on distribution deal in US
Brief: Immuron Executes Exclusive Distribution Agreement For Proibs In The United States
Brief: Immuron Reports FY26 Preliminary Results
Brief: Immuron Posts FY Revenue From Ordinary Activities Of A$7.71 Million
Brief: Immuron Logs FY Global Sales A$7.7 Million
Australia's Immuron rises as company seeks partnership for new drug
Brief: Immuron Seeks Partners To Advance Clinical Development Of IMM-529
Australia's Immuron jumps on upbeat quarterly sales growth
Brief: Immuron Global Q3 Sales AUD$1.5 Million
Brief: Immuron Reports Hy26 Results And Strategic Reset
Brief: Immuron Says Phillip Hains Resigns As CFO
Brief: Immuron Reports H1 Global Travelan Sales AUD$4.2 Mln
Brief: Immuron New U.S. Department Of Defense Award & Clinical Trial Update
Brief: Immuron Receives US Department Of Defense Award For Oral Therapeutics Development
Australia's Immuron hits near 1-month high on US Defense-funded research
Brief: Immuron Says IMM-529 IND Approved By FDA
Brief: Immuron Announces Clinical Trial Update
Brief: Immuron Q1 Fy26 YoY Growth
Brief: Immuron Posts Q1 FY26 Global Sales AUD$2.0 Million